HomeAI · summaries
Storia in 20 fonti
Guerra por la obesidad: Novo Nordisk (Ozempic) demanda a Eli Lilly por publicidad engañosa
La farmacéutica danesa acusa a su rival estadounidense de utilizar estudios desactualizados para promocionar sus alternativas Zepbound y Mounjaro
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Ozempic Maker Novo Nordisk Sues Eli Lilly For Deceptive Advertising
The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.
- ·
index.hr
Proizvođač Ozempica tužio konkurenta
FARMACEUTSKA tvrtka Novo Nordisk tuži konkurenta Eli Lilly zbog, kako navodi, lažnog prikazivanja njegovih lijekova za mršavljenje kao superiornijih na temelju zastarjelih studija.
- ·
biopharmadive.com
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…
- ·
www1.folha.uol.com.br
Dona do Ozempic acusa criadora do Mounjaro de fazer propaganda com dados falsos sobre eficácia
Eli Lilly não responde a pedido de comentário após processo da Novo Nordisk nos EUA
- ·
nbcnews.com
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says…
- ·
eu.usatoday.com
Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads
Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.
- ·
economictimes.indiatimes.com
Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug
Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its…
- ·
zerohedge.com
GLP-1 Fight: Novo Sues Eli Lilly Over Nationwide "Deceptive Advertising" Campaign
"Through this action, Novo Nordisk is seeking a permanent injunction requiring Lilly to pull its misleading comparative advertising across all platforms... "
- ·
france24.com
Pharma heavyweights clash over anti-obesity drug ads
Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing…
- ·
efe.com
El fabricante de Ozempic demanda a su rival Eli Lilly por publicidad engañosa - EFE
Novo Nordisk, fabricante del medicamento contra la obesidad Ozempic, demanda a su rival Eli Lilly por publicidad engañosa.
- ·
lecho.be
Novo Nordisk intente un procès à Eli Lilly pour publicité mensongère sur ses traitements anti-obésité
Le duel entre les leaders du marché de l'anti-obésité se poursuit devant les tribunaux américains. Le fabricant du Wegovy a saisi la justice, estimant que les publicités pour…
- ·
fiercepharma.com
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads
Novo Nordisk has accused rival Eli Lilly of runnin | Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public…
- ·
oglobo.globo.com
Briga das canetas emagrecedoras: dona do Ozempic processa fabricante do Mounjaro nos EUA por propaganda enganosa
Empresa dinamarquesa alega que a rival usou comparações com doses antigas do Wegovy para favorecer o Zepbound e pede a suspensão imediata da campanha
- ·
wiwo.de
Pharmaindustrie: Novo Nordisk verklagt US-Rivalen Eli Lilly
Das dänische Unternehmen sieht sich in einer Werbung seines US-Konkurrenten falsch dargestellt und klagt. Worum es in den Streit geht.
- ·
milanofinanza.it
Novo Nordisk porta Eli Lilly in tribunale: pubblicità ingannevole sui farmaci anti-obesità | MilanoFinanza News
La casa farmaceutica danese accusa la rivale americana di aver promosso Zepbound e Mounjaro con confronti «falsi e fuorvianti» rispetto a Wegovy e Ozempic. Nel mirino una campagna…
- ·
eluniversal.com.mx
Novo Nordisk, fabricante de Ozempic y Wegovy, demanda a Eli Lilly; acusa publicidad engañosa sobre medicamentos contra obesidad y diabetes
La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound
- ·
ilpost.it
L'azienda Novo Nordisk, che produce l'Ozempic, ha fatto causa alla concorrente Eli Lilly per pubblicità ingannevole
La multinazionale danese Novo Nordisk, che produce l’Ozempic e il Wegovy – due farmaci utilizzati per contrastare il diabete e l’obesità (cambiano i dosaggi) – ha fatto causa…
- ·
dw.com
Ozempic maker sues US rival over ad campaign
Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.
- ·
elpais.com
Novo Nordisk demanda a Eli Lilly por “publicidad engañosa” de Zepbound frente a Ozempic y Wegovy
La farmacéutica danesa acusa a su competidora estadounidense de comparar la eficacia de sus medicamentos en su dosis más alta con una menor de Wegovy y Ozempic
- ·
forbes.it
Novo Nordisk fa causa alla rivale Eli Lilly per pubblicità ingannevole sui farmaci GLP-1
Novo Nordisk cita in giudizio Eli Lilly: sotto accusa campagne basate su dati superati per esagerare l'efficacia dei farmaci GLP-1